Selecta Biosciences Inc (SELB) Given Consensus Recommendation of “Hold” by Brokerages

Selecta Biosciences Inc (NASDAQ:SELB) has received an average rating of “Hold” from the eight analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $31.75.

SELB has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, August 29th. Stifel Nicolaus initiated coverage on shares of Selecta Biosciences in a research report on Friday, September 14th. They issued a “buy” rating and a $24.00 price objective for the company. BidaskClub cut shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Mizuho restated a “buy” rating and issued a $30.00 price objective on shares of Selecta Biosciences in a research report on Thursday, August 9th. Finally, Canaccord Genuity restated a “buy” rating and issued a $40.00 price objective on shares of Selecta Biosciences in a research report on Wednesday, July 11th.

SELB opened at $13.31 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.96 and a quick ratio of 4.96. Selecta Biosciences has a 12 month low of $7.95 and a 12 month high of $24.02. The firm has a market capitalization of $348.26 million, a P/E ratio of -4.16 and a beta of -3.47.

Selecta Biosciences (NASDAQ:SELB) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($0.84) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.16). As a group, sell-side analysts forecast that Selecta Biosciences will post -3.07 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northern Trust Corp increased its position in shares of Selecta Biosciences by 11.9% in the 2nd quarter. Northern Trust Corp now owns 156,708 shares of the company’s stock valued at $2,076,000 after buying an additional 16,615 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Selecta Biosciences by 27.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock valued at $626,000 after buying an additional 10,114 shares in the last quarter. Millennium Management LLC bought a new position in Selecta Biosciences during the 2nd quarter worth about $1,583,000. Proxima Capital Management LLC bought a new position in Selecta Biosciences during the 2nd quarter worth about $1,075,000. Finally, BlackRock Inc. increased its holdings in Selecta Biosciences by 40.4% during the 2nd quarter. BlackRock Inc. now owns 884,564 shares of the company’s stock worth $11,721,000 after purchasing an additional 254,586 shares in the last quarter. Institutional investors and hedge funds own 48.74% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Read More: Penny Stocks, Risk and Reward Factors

Analyst Recommendations for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply